WEBULL
WebtradeDownload

What Is Drawing Attention To CSPC Pharmaceutical Group (SEHK:1093)?

Simply Wall St · 2d ago

CSPC Pharmaceutical Group (SEHK:1093) just pushed its R&D pipeline further into the clinic, with fresh Phase III and Phase II trial launches and new oncology trial approvals attracting renewed attention to the stock.

Against that clinical backdrop, CSPC Pharmaceutical Group’s share price has come under pressure recently. The stock is down 15.1% on a 30-day share price return and 8.4% over the past week, even as the latest oncology and RSV updates land on the tape.

The share price now sits at HK$7.97. When you zoom out, the picture looks very different, with a 1-year total shareholder return of 8.2% and a 3-year total shareholder return of 31.5%, suggesting that longer term holders have still been rewarded despite the recent loss of momentum.

Scan 195 high quality undervalued stocks that, like CSPC Pharmaceutical Group, pair active product pipelines with solid financial profiles and could be preparing for their next move.

That kind of short term drop, combined with an active R&D slate, raises a simple puzzle: Are you seeing cracks in CSPC Pharmaceutical Group’s business, or just a swing in mood that leaves the valuation out of sync?

Preferred P/E of 10.4x for CSPC Pharmaceutical Group: Is it justified?

CSPC Pharmaceutical Group changes hands at a P/E of 10.4x based on its recent share price of HK$7.97. Various benchmarks point to a higher level, which suggests the market is pricing the stock below peers that share similar fundamentals.

The P/E ratio compares what investors are paying for each dollar of earnings. For a healthcare producer with established drugs, a P/E measure often reflects how the market weighs current profitability against expectations for future profits and the perceived risk around those earnings.

For CSPC Pharmaceutical Group, the current valuation sits against a mixed earnings picture. Net income of CN¥7,428.5m and high quality earnings are paired with a one year earnings increase of 92.7% after a five year period where earnings declined by 5.9% per year. Forecasts point to average earnings declines of 7.7% per year over the next three years, which may be one reason investors are not assigning a richer multiple, despite profit margins improving to 23.7% from 14.8%.

Compared with the Hong Kong pharmaceuticals sector, the 10.4x P/E is framed as good value against both the industry average of 13.3x and a peer average of 18.7x. This implies CSPC Pharmaceutical Group trades at a clear discount to other drug makers. The SWS fair P/E ratio of 16.8x is also materially higher than where the stock currently trades, which suggests the multiple could move closer to that level if the market reassesses earnings durability.

Explore the SWS fair ratio for CSPC Pharmaceutical Group.

Result: Price-to-earnings of 10.4x (UNDERVALUED)

Still, two pressure points linger for CSPC Pharmaceutical Group: annual net income contraction of 7.7% and exposure to Mainland China, where over two thirds of revenue originates.

Find out about the key risks to this CSPC Pharmaceutical Group narrative.

Another view on CSPC Pharmaceutical Group’s value

The P/E gap already points to CSPC Pharmaceutical Group looking inexpensive next to peers. A different lens comes from the SWS DCF model, which estimates fair value at HK$14.19 per share compared with the current HK$7.97. That signals a wide upside gap. The key question is whether the cash flow assumptions prove too generous or not cautious enough.

Look into how the SWS DCF model arrives at its fair value.

1093 Discounted Cash Flow as at Oct 2026
1093 Discounted Cash Flow as at Oct 2026

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out CSPC Pharmaceutical Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 195 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Mixed signals around CSPC Pharmaceutical Group can be confusing, so act promptly, consider both the downside and upside factors, and ground your view in the data with 3 key rewards and 2 important warning signs

Looking for more investment ideas beyond CSPC Pharmaceutical Group?

If you stop at CSPC Pharmaceutical Group, you risk missing other opportunities. Use the screener to quickly surface fresh ideas that match your style.